Description

While the use of home mechanical ventilation (HMV) in the form of noninvasive ventilation to treat COPD with chronic respiratory failure (COPD-CRF) is increasing, fewer than 5% of eligible patients in the US. are currently using this therapy. One explanation for the slow adoption of this potentially lifesaving treatment maybe the small number of older studies showing benefit. This presentation will review three recently published peer-reviewed, real-world claims data studies (Medicare) describing the association of HMV with significant decreases in all-cause mortality, hospitalizations, and healthcare spending in patients with COPD-CR.

 

Learning Objectives

1. Describe which COPD-CRF patients benefit from HMV

2. Discuss the optimal time to begin HMV following a diagnosis of COPD-CRF

3. Describe the reduction in mortality, hospitalizations, and healthcare spending associated with HMV use in COPD-CRF patients

 

Faculty Bio

William D. Frazier, MD is currently the Chief Medical Officer (CMO) of Viemed,  one of the nation’s largest providers of home mechanical ventilation (HMV) for patients with chronic respiratory failure. He also serves as the CMO of Verustat, a start-up remote patient monitoring company. Prior to this, Dr. Frazier worked for more than 30 years as a full-time practicing pulmonologist. Dr. Frazier has experience conducting clinical research projects, including trials evaluating new treatment options for COPD. He was first author on three articles published in peer reviewed journals in 2020, 2021, and 2022 reporting the significant benefits seen in patients using HMV as therapy for COPD.